MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains

    M. Siddiqui, V. Evidente, P. Bhargava, B. Navia, E. Pappert (Winston-Salem, NC, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…
  • MDS Virtual Congress 2020

    Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

    F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

    Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
  • MDS Virtual Congress 2020

    A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes

    A. Thach, J. Sutphin, J. Coulter, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…
  • MDS Virtual Congress 2020

    Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes

    A. Thach, N. Kirson, M. Zichlin, I. Dieye, E. Pappert, G. Williams (Marlborough, MA, USA)

    Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…
  • 2019 International Congress

    Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study

    R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, K. Chaudhuri, T. Henriksen, T. van Laar, D. Lockhart, A. Lees (London, United Kingdom)

    Objective: To evaluate the long-term safety and efficacy of apomorphine infusion (APO) in PD patients with motor fluctuations despite optimised oral therapy. Background: The randomised,…
  • 2019 International Congress

    Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis

    W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia (Houston, TX, USA)

    Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…
  • 2019 International Congress

    Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

    C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

    Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…
  • 2019 International Congress

    A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes

    F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, F. Agbo, R. Kleiman, D. Blum, B. Navia (Rome, Italy)

    Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…
  • 2019 International Congress

    Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

    F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

    Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…
  • 2019 International Congress

    Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

    R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

    Objective: To establish a registry of PD patients in Thailand treated with subcutaneous apomorphine (APO) injection or infusion to allow prospective data collection from the…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley